Trump Administration Backs Psychedelics: FDA Approval and Delivery Challenges
Following recent signals from the Trump administration supporting the psychedelic renaissance, the U.S. Food and Drug Administration (FDA) is facing critical questions regarding how compounds like psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) ... Read More